{"count": 8, "results": [{"_id": "31512365", "pmid": 31512365, "title": "Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study.", "journal": "Diabetes Obes Metab", "authors": ["Ji L", "Sun N", "Zhang Y", "Zhang L", "Shen S", "Wang X", "Li Q", "Dong L", "Ren W", "Qi L", "Li Y", "Yan S", "Cheng W", "Kuang H", "Li G"], "date": "2020-02-01T00:00:00Z", "doi": "10.1111/dom.13884", "meta_date_publication": "2020 Feb", "meta_volume": "22", "meta_issue": "2", "meta_pages": "158-166", "score": 50267.176, "text_hl": "AIM: To investigate the effectiveness of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in delaying or preventing progression to @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ in a Chinese population with @<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@impaired glucose regulation@@@ (@<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@IGR@@@). ", "citations": {"NLM": "Ji L, Sun N, Zhang Y, Zhang L, Shen S, Wang X, Li Q, Dong L, Ren W, Qi L, Li Y, Yan S, Cheng W, Kuang H, Li G. Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study. Diabetes Obes Metab. 2020 Feb;22(2):158-166. PMID: 31512365", "BibTeX": "@article{31512365, title={Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study.}, author={Ji L and Sun N and Zhang Y and Zhang L and Shen S and Wang X and Li Q and Dong L and Ren W and Qi L and Li Y and Yan S and Cheng W and Kuang H and Li G}, journal={Diabetes Obes Metab}, volume={22}, number={2}, pages={158-166}}"}}, {"_id": "37414069", "pmid": 37414069, "title": "Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.", "journal": "Lancet Diabetes Endocrinol", "authors": ["Zhang L", "Zhang Y", "Shen S", "Wang X", "Dong L", "Li Q", "Ren W", "Li Y", "Bai J", "Gong Q", "Kuang H", "Qi L", "Lu Q", "Cheng W", "Liu Y", "Yan S", "Wu D", "Fang H", "Hou F", "Wang Y", "Yang Z", "Lian X", "Du J", "Sun N", "Ji L", "Li G", "China Diabetes Prevention Program Study Group"], "date": "2023-07-03T00:00:00Z", "doi": "10.1016/S2213-8587(23)00132-8", "meta_date_publication": "2023 Jul 3", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50261.723, "text_hl": "Safety and effectiveness of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ in a Chinese population with @<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@impaired glucose regulation@@@: a multicentre, open-label, randomised controlled trial.", "citations": {"NLM": "Zhang L, Zhang Y, Shen S, Wang X, Dong L, Li Q, Ren W, Li Y, Bai J, Gong Q, Kuang H, Qi L, Lu Q, Cheng W, Liu Y, Yan S, Wu D, Fang H, Hou F, Wang Y, Yang Z, Lian X, Du J, Sun N, Ji L, Li G, China Diabetes Prevention Program Study Group. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2023 Jul 3;():. PMID: 37414069", "BibTeX": "@article{37414069, title={Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.}, author={Zhang L and Zhang Y and Shen S and Wang X and Dong L and Li Q and Ren W and Li Y and Bai J and Gong Q and Kuang H and Qi L and Lu Q and Cheng W and Liu Y and Yan S and Wu D and Fang H and Hou F and Wang Y and Yang Z and Lian X and Du J and Sun N and Ji L and Li G and China Diabetes Prevention Program Study Group}, journal={Lancet Diabetes Endocrinol}}"}}, {"_id": "32368117", "pmid": 32368117, "pmcid": "PMC7183773", "title": "Correlation Between Circulating Levels of Secreted Frizzled-Related Protein 5 and Type 2 Diabetic Patients and Subjects with Impaired-Glucose Regulation", "journal": "Diabetes Metab Syndr Obes", "authors": ["He X", "Ma H"], "date": "2020-04-22T00:00:00Z", "doi": "10.2147/DMSO.S242657", "meta_date_publication": "2020", "meta_volume": "13", "meta_issue": "", "meta_pages": "1243-1250", "score": 50250.64, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Treatment", "citations": {"NLM": "He X, Ma H. Correlation Between Circulating Levels of Secreted Frizzled-Related Protein 5 and Type 2 Diabetic Patients and Subjects with Impaired-Glucose Regulation Diabetes Metab Syndr Obes. 2020;13():1243-1250. PMID: 32368117", "BibTeX": "@article{32368117, title={Correlation Between Circulating Levels of Secreted Frizzled-Related Protein 5 and Type 2 Diabetic Patients and Subjects with Impaired-Glucose Regulation}, author={He X and Ma H}, journal={Diabetes Metab Syndr Obes}, volume={13}, pages={1243-1250}}"}}, {"_id": "31802616", "pmid": 31802616, "title": "Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes.", "journal": "Diabetes Obes Metab", "authors": ["Daniele G", "Tura A", "Dardano A", "Bertolotto A", "Bianchi C", "Giusti L", "Kurumthodathu JJ", "Del Prato S"], "date": "2020-04-01T00:00:00Z", "doi": "10.1111/dom.13940", "meta_date_publication": "2020 Apr", "meta_volume": "22", "meta_issue": "4", "meta_pages": "648-657", "score": 50247.46, "text_hl": "AIM: To investigate the effect of @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@ (@CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@SITA@@@) and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@) monotherapy as well as in combination (@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@+@CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@SITA@@@) on beta-cell function and @GENE_INS @GENE_3630 @@@insulin@@@ sensitivity in @SPECIES_9606 @@@women@@@ with recent @DISEASE_Diabetes_Gestational @DISEASE_MESH:D016640 @@@gestational diabetes@@@ (GDM) and @<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@impaired glucose regulation@@@ (IGR: @DISEASE_Hypoglycemia @DISEASE_MESH:D007003 @@@impaired fasting glucose@@@ and/or @DISEASE_Glucose_Intolerance @DISEASE_MESH:D018149 @@@impaired glucose tolerance@@@). ", "citations": {"NLM": "Daniele G, Tura A, Dardano A, Bertolotto A, Bianchi C, Giusti L, Kurumthodathu JJ, Del Prato S. Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes. Diabetes Obes Metab. 2020 Apr;22(4):648-657. PMID: 31802616", "BibTeX": "@article{31802616, title={Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes.}, author={Daniele G and Tura A and Dardano A and Bertolotto A and Bianchi C and Giusti L and Kurumthodathu JJ and Del Prato S}, journal={Diabetes Obes Metab}, volume={22}, number={4}, pages={648-657}}"}}, {"_id": "29561188", "pmid": 29561188, "title": "SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.", "journal": "Endocr Pract", "authors": ["Elkind-Hirsch KE", "Paterson MS", "Shaler D", "Gutowski HC"], "date": "2018-04-01T00:00:00Z", "doi": "10.4158/EP-2017-0251", "meta_date_publication": "2018 Apr", "meta_volume": "24", "meta_issue": "4", "meta_pages": "361-368", "score": 50077.316, "text_hl": "@DISEASE_SHORT_syndrome @DISEASE_MESH:C537327 @@@SHORT-@@@TERM SITAGLIPTIN-@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@METFORMIN@@@ THERAPY IS MORE EFFECTIVE THAN @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@METFORMIN@@@ OR PLACEBO IN PRIOR GESTATIONAL DIABETIC @SPECIES_9606 @@@WOMEN@@@ WITH @<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@IMPAIRED GLUCOSE REGULATION@@@.", "citations": {"NLM": "Elkind-Hirsch KE, Paterson MS, Shaler D, Gutowski HC. SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION. Endocr Pract. 2018 Apr;24(4):361-368. PMID: 29561188", "BibTeX": "@article{29561188, title={SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.}, author={Elkind-Hirsch KE and Paterson MS and Shaler D and Gutowski HC}, journal={Endocr Pract}, volume={24}, number={4}, pages={361-368}}"}}, {"_id": "21802961", "pmid": 21802961, "title": "Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone.", "journal": "Cytokine", "authors": ["Zhang L", "Li L", "Yang M", "Liu H", "Yang G"], "date": "2011-11-01T00:00:00Z", "doi": "10.1016/j.cyto.2011.07.003", "meta_date_publication": "2011 Nov", "meta_volume": "56", "meta_issue": "2", "meta_pages": "399-402", "score": 50067.355, "text_hl": "The aim of the present study is to investigate the effects of @CHEMICAL_Rosiglitazone @CHEMICAL_MESH:D000077154 @@@rosiglitazone@@@ therapy on plasma @GENE_SERPINA12 @GENE_145264 @@@vaspin@@@ in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ @SPECIES_9606 @@@patients@@@ (T2DM) inadequately controlled on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alone. A total of 105 subjects, including 37 subjects with @DISEASE_Glucose_Intolerance @DISEASE_MESH:D018149 @@@normal glucose tolerance@@@ (@DISEASE_Glucose_Intolerance @DISEASE_MESH:D018149 @@@NGT@@@), 37 subjects with @<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@impaired glucose regulating@@@ (@<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@IGR@@@), and 31 T2DM @SPECIES_9606 @@@patients@@@ with poor glycemic control on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alone were enrolled in this study. ", "citations": {"NLM": "Zhang L, Li L, Yang M, Liu H, Yang G. Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone. Cytokine. 2011 Nov;56(2):399-402. PMID: 21802961", "BibTeX": "@article{21802961, title={Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone.}, author={Zhang L and Li L and Yang M and Liu H and Yang G}, journal={Cytokine}, volume={56}, number={2}, pages={399-402}}"}}, {"_id": "29021207", "pmid": 29021207, "title": "Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.", "journal": "Diabetes Care", "authors": ["Herman WH", "Pan Q", "Edelstein SL", "Mather KJ", "Perreault L", "Barrett-Connor E", "Dabelea DM", "Horton E", "Kahn SE", "Knowler WC", "Lorenzo C", "Pi-Sunyer X", "Venditti E", "Ye W", "Diabetes Prevention Program Research Group"], "date": "2017-12-01T00:00:00Z", "doi": "10.2337/dc17-1116", "meta_date_publication": "2017 Dec", "meta_volume": "40", "meta_issue": "12", "meta_pages": "1668-1677", "score": 50061.875, "text_hl": "Impact of Lifestyle and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Interventions on the Risk of Progression to @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ and Regression to Normal @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@Glucose@@@ Regulation in @DISEASE_Overweight @DISEASE_MESH:D050177 @@@Overweight@@@ or @DISEASE_Obesity @DISEASE_MESH:D009765 @@@Obese@@@ People With @<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@Impaired Glucose Regulation@@@.", "citations": {"NLM": "Herman WH, Pan Q, Edelstein SL, Mather KJ, Perreault L, Barrett-Connor E, Dabelea DM, Horton E, Kahn SE, Knowler WC, Lorenzo C, Pi-Sunyer X, Venditti E, Ye W, Diabetes Prevention Program Research Group. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care. 2017 Dec;40(12):1668-1677. PMID: 29021207", "BibTeX": "@article{29021207, title={Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.}, author={Herman WH and Pan Q and Edelstein SL and Mather KJ and Perreault L and Barrett-Connor E and Dabelea DM and Horton E and Kahn SE and Knowler WC and Lorenzo C and Pi-Sunyer X and Venditti E and Ye W and Diabetes Prevention Program Research Group}, journal={Diabetes Care}, volume={40}, number={12}, pages={1668-1677}}"}}, {"_id": "28228317", "pmid": 28228317, "title": "Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.", "journal": "Fertil Steril", "authors": ["Elkind-Hirsch KE", "Paterson MS", "Seidemann EL", "Gutowski HC"], "date": "2017-01-01T00:00:00Z", "doi": "10.1016/j.fertnstert.2016.09.023", "meta_date_publication": "2017 Jan", "meta_volume": "107", "meta_issue": "1", "meta_pages": "253-260.e1", "score": 50049.85, "text_hl": "OBJECTIVE: To evaluate efficacy with the dipeptidyl peptidase-4 inhibitor @CHEMICAL_saxagliptin @CHEMICAL_MESH:C502994 @@@saxagliptin@@@ (@CHEMICAL_saxagliptin @CHEMICAL_MESH:C502994 @@@SAXA@@@), @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin extended release@@@ (@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@), and combination (SAXA-MET) in @SPECIES_9606 @@@patients@@@ with @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@polycystic ovary syndrome@@@ (@DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@) and @<m>DISEASE_Wolfram_Like_Syndrome_Autosomal_Dominant</m> @DISEASE_MESH:C565631 @@@impaired glucose regulation@@@. ", "citations": {"NLM": "Elkind-Hirsch KE, Paterson MS, Seidemann EL, Gutowski HC. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study. Fertil Steril. 2017 Jan;107(1):253-260.e1. PMID: 28228317", "BibTeX": "@article{28228317, title={Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.}, author={Elkind-Hirsch KE and Paterson MS and Seidemann EL and Gutowski HC}, journal={Fertil Steril}, volume={107}, number={1}, pages={253-260.e1}}"}}]}